EUCTR2012-003344-74-BE进行中（未招募）不适用
A phase I/II feasibility study of the combination of panobinostat and decitabine prior to donor lymphocyte infusion in recipients of allogeneic stem cell transplantation with poor and very poor risk AML - HOVON 116 AM
HOVON Foundation0 个研究点目标入组 100 人开始时间: 2013年11月18日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients with poor risk or very poor risk AML or RAEB with IPSS = 1.5.
- •Eligibility for continuation with intensive induction/consolidation chemotherapy
- •Eligible for allogeneic donor search (related/unrelated)
- •18-70 years, inclusive
- •Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •History of active malignancy during the past 2 years with the exception of basal carcinoma of the skin or carcinoma in situ” of the cervix or breast
- •Known HIV-positivity
- •Pregnant or breast-feeding female patients
研究者
相似试验
进行中（未招募）
1 期
A study about the treatment of patients with a specific type of AML with a combination of panobinostat and midostaurin during 1 year after allogeneic stem cell transplantation .EUCTR2017-002335-42-NLHOVON Foundation40
已完成
不适用
A phase Ib feasibility study of the combination of panobinostat and midostaurin in recipients of allogeneic stem cell transplantation with FLT3-ITD AMAcute myeloid leukemiaAMLNL-OMON48580HOVO15
进行中（未招募）
1 期
Study of the Combination of Acalabrutinib and Vistusertib in Subjects with Relapsed/Refractory B-cell MalignanciesPart 1: De novo Diffuse large B-cell lymphoma (DLBCL), Transformed DLBCL and Richter syndrome (RS). Part 2: De novo Germinal center B-cell (GCB) DLBCL and De novo non-GCB DLBCLMedDRA version: 20.0 Level: PT Classification code 10012822 Term: Diffuse large B-cell lymphoma refractory System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10058728 Term: Richter's syndrome System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-003736-21-GBAcerta Pharma BV71
已完成
2 期
A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer.10027656Breast cancerNL-OMON35692ovartis5
进行中（未招募）
1 期
A clinical study investigating the combination of RAD001 with trastuzumaband paclitaxel in patients with breast cancermetastatic breast cancerEUCTR2006-001596-37-BEovartis Pharma Services AG55